ABSTRACT
(CFTR) (2) , and P-glycoprotein, a 170-to 180-kD plasma membrane glycoprotein (3) . The most generally accepted hypothesis for MDR suggests that P-glycoprotein uses ATP to power a molecular pump that removes chemotherapeutic molecules from the cell (ref. 4 ; reviewed in ref. 3) . This model proposes that chemotherapeutic agents diffuse down a concentration gradient into the cell and that the pump either transports the drugs out of the cytosol or serves as a "flippase" to expel them from the bilayer (5) .
The data presented in this communication support an additional mechanism of MDR by which changes in intracellular pH alter the transmembrane partitioning or intracellular sequestration of drugs. Cytosolic pH affects protonation of these drugs (typically weak bases, with pK values between 7.4 and 8.2; refs. [6] [7] [8] , affinity of intracellular sites for drug binding, and/or secretion from organelles which accumulate the drugs. The pH of tumor cells is considerably more acidic than that of normal (9) or multidrug-resistant (10) cells. Drugs which partition across the membrane would be protonated and ionically trapped in the cytosol in their biologically active form [the charged form of these drugs binds to their targets such as DNA (11) (12) (13) (14) (15) , RNA (15, 16) , and tubulin (17, 18) diameter, 1.6 cm) suspended in a 200-ml beaker with RPMI 1640. The RPMI 1640 in the beaker was maintained at 37C and kept aerated with an aquarium airstone with 0.03%, 2%, 5%, or 10% CO2 in air. The stirred bathing medium could be changed to vary the concentrations of CO2 or drugs in the dialysis bag. For measurement in a spectrofluorometer an emission scan was taken from 520 to 700 nm with excitation at 488 nm and 514 nm. The cells were calibrated, as described above for the fibroblasts, for both excitations and the results at each were compared. For measurement on a fluorescenceactivated cell sorter (Becton Dickinson FACStarPLUS) the cells were pumped at 0.38 ml/min with an Ismatec peristaltic pump (Cole-Palmer) and excited with an argon laser at 514 nm, and emission was monitored with filters at 570/26 nm and 630/30 nm. For measuring daunomycin concentration, the cells were excited at 488 nm and emission monitored at 570 nm.
RESULTS
Daunomycin Accumulates in Cells. Daunomycin, a chemotherapeutic agent, fluoresces maximally at 595 nm when excited at 488 nm. These optical properties enable monitoring the drug in living cells. NIH 3T3 fibroblasts were incubated in the presence of 5 1LM daunomycin for 30 min and examined on an inverted fluorescence microscope. Since the fluorescence spectrum of daunomycin is not affected by pH (data not shown), the fluorescent images of increasing cytosolic daunomycin fluorescence reflect accumulation of the drug. The concentration of daunomycin in the cytosol ( Fig. 1 ) was higher than in the surrounding medium, with the highest concentration in the nucleoli and two of the major acidic compartments of the cell (trans-Golgi and lysosomal), as previously reported (19) . Similar patterns of intracellular accumulation were observed for cells incubated with doxorubicin and with several strains of NIH 3T3 fibroblasts and with myeloma cells growing in suspension. Daunomycin binds DNA with great affinity and RNA to a lesser extent (15, 16) . Binding to tightly packed DNA in the chromatin results in quenching of the daunomycin fluorescence, whereas binding to nucleoli yields fluorescent structures.
The pH Is Different in Drug-Sensitive and Drug-Resistant Cells. The NIH 3T3 fibroblasts and myeloma cells were loaded with SNARF-1 AM, a dye whose fluorescence emission is pH sensitive. When excited at 514 nm, its emission maximum is at 630 nm in a basic environment and at 570 nm when acidic. Ratioing of fluorescence emission is used as a quantitative measure of the pH, independent of cell volume or dye concentration. The pH of the myeloma cells, as measured in a fluorescence-activated cell sorter or spectrofluorometer, was 7.1 for the drug-sensitive cells (8226) (21) . Our results are consistent with published measurements in 5% CO2 (22) .
The pH of myeloma cells, grown in suspension, was examined in both a FACS and a spectrofluorometer. The emission spectrum of SNARF-1 in drug-sensitive cells (Fig.  2A, black line) and MDR cells (gray line) is shown at 5% CO2 (solid line) or 2% CO2 (dotted line). The pH of sensitive cells incubated with a 2% CO2 (measured as the ratio of the emission at 630 nm to that at 585 nm, Fig. 2A , dotted black line) was indistinguishable from the pH of the resistant cells at a CO2 of 5% (solid gray line). This demonstrates that varying CO2 concentration can be used to shift the pH of the drug-sensitive cells to a value as alkaline as that of the resistant cells. Likewise, the pH of the drug-sensitive cells in 5% CO2 (Fig. 2B) was comparable to the pH in resistant cells at 10%0 CO2 (Fig. 2B) (Fig. 3A,  red background) . The partial pressure of CO2 perfusing the solution was shifted from 5% to 2% (Fig. 3A, blue background) . The daunomycin fluorescence rapidly decreased in the cells. Upon returning the cells to 5% CO2 (red background), the daunomycin fluorescence increased to its starting level. The pattern remained unchanged upon repeated cycling between 2% and 5% CO2. The intracellular daunomycin fluorescence was quantified for a number of cells (Fig.   3B ). In all cases, the cellular fluorescence decreased when the CO2 level was lowered (more alkaline pH) and the fluorescence increased when CO2 was increased. These changes were rapid, repeatable, and reversible.
The experiment was repeated with both drug-sensitive (8226) and drug-resistant (DOX40) myeloma cells with similar results. Cells were loaded with 20 pM daunomycin in medium equilibrated with 5% CO2. While the daunomycin fluorescence was monitored, CO2 was sequentially shifted to 2%, 0.03%, 2%, 5%, 10%1, and 5% (Fig. 4) . This cycle was repeated. The cellular daunomycin fluorescence decreased when the CO2 level was lowered and increased when the CO2 level was raised. These changes were completely reversible and occurred at the same rate in all intracellular compartments.
Similar reversible increases of cellular drug levels were also observed when the pH was transiently shifted to alkaline with 20 mM NH4C1 for 2 min (data not shown). Reversible increases of cytosolic drug levels were observed when the pH was transiently shifted to acidic with 2.5 mM NaN3 for 2 min (data not shown). DISCUSSION Fluorescent chemotherapeutic agents accumulate in tumor cells (see Fig. 1 ). This could be a consequence of decreased drug influx, increased intracellular trapping, and/or increased drug efflux. There are two general mechanisms for drug transport: active and passive. An active-transport model for MDR has been proposed based on the observations that transport is blocked by metabolic inhibitors such as azide and that transport is associated with the expression of P-glycoprotein, an ATP-binding protein which is a member of a family of membrane transporters.
The passive-diffusion models are based on the observation that these drugs are sufficiently hydrophobic to cross membranes. The asymmetric distribution of the drugs is assumed to be the consequence ofan asymmetry of chemical potential (such as ApH, voltage, and ionic concentrations). For example, the higher rate of aerobic glycolysis in tumors and the hypoxic conditions surrounding cells within a tumor mass cause an acidic environment (9) . This increased proton concentration has two effects. First, the drugs that are weak bases will be protonated and trapped in the cytosol. Second, the binding of each of these drugs to their cytosolic targets, such as tubulin (17, 18) optimum. Conversely, an increased pH both decreases intracellular drug accumulation and reduces binding to intracellular targets.
Passive transport of drugs in conjunction with a trapping mechanism is consistent with a number of independent observations. (i) In simple systems such as erythrocyte ghosts (23) The medium initially was equilibrated with 5% CO2 (the first 7 frames, red background). CO2 was shifted to 2% for 2 min (blue background) and there was a substantial decrease in the cellular daunomycin fluorescence. Upon returning to 5% C02 (red background) the cellular daunomycin fluorescence returned. The cells were repeatedly cycled between 5% CO2 (red background) and 2% CO2 (blue background). The daunomycin concentration is pseudocolored with the lowest level in black and increasing concentrations in blue, green, red, and yellow. (xS0.) (B) Quantification of the effect of changes in CO2 concentration on daunomycin fluorescence in NIH 3T3 cells. The daunomycin fluorescence was quantified for six different cells as CO2 was shifted between 2% and 5%. Reducing the CO2 level raises the cytosolic pH and reduces the cell-associated daunomycin fluorescence. These effects were completely reversible and were repeated on the same cells many times. distribution of these drugs is determined by the ApH. (ii) The cytosolic pH of tumor cells increases with increased MDR (25) . (iii) Transfection of cells with P-glycoprotein causes an alkaline shift of cytosolic pH (10) . (iv) Verapamil, which reverses MDR, partially reverses this shift of cytosolic pH (25) .5%/ 27). (v) Drug influx is slower in resistant cells (4, (28) (29) (30) (31) (32) (33) (34) (35) (36) , which is consistent with differences in the rate oftrapping and inconsistent with an active efflux model. (vi) Drugs which acidify the cytosol, such as amiloride, reverse MDR (37) .
As shown, the passive-trapping hypothesis can account for changes in cellular accumulation of chemotherapeutic agents that are weak bases. What about the rest? None are negatively charged but some, such as colchicine, are neutral. Each of these drugs has an intracellular target. Binding of colchicine to its target, the extremely acidic carboxyl terminus of a-tubulin (38) , is pH dependent with an optimum of pH 6.7-6.8 (39) . Any alkaline shift of the pH decreases the binding of colchicine and could protect the cell from this chemotherapeutic agent.
Multiple forms of non-P-glycoprotein MDR have been observed. The passive-transport theory predicts that each affects a common feature-regulation of cellular pH. One protein responsible for non-P-glycoprotein-mediated MDR has been cloned and demonstrated to be a vacuolar H+-ATPase subunit (1) . Other mechanisms for MDR may use pH to affect drug distribution either by selective sequestrationi.e., drug uptake by lysosomes-or by modifications in the secretory pathway (40) . Consistent with this hypothesis is the observation of an increase in nonspecific adsorptive endocytosis in anthracycline-and vinca alkaloid-resistant cells (41) , as well as an increase in membrane traffic in daunomycinresistant cells (42) . In drug-resistant cells, there is a significant rate of exocytosis of lysosomal enzymes, suggesting a modification of the endocytic pathway. Furthermore, an enhanced rate of exocytosis of vesicles containing a H+-ATPase could be a means by which cytosolic pH is raised, as has been observed in plant and animal cells (43, 44) .
These results demonstrate that the passive-trapping model is sufficient to account for the enhanced sensitivity of tumors to anticancer drugs and the decreased sensitivity in MDR. When the pH of drug-sensitive cells is shifted to the level observed in drug-resistant cells, they no longer accumulate chemotherapeutic agents. Likewise, when drug-resistant cells are shifted to the level observed in drug-sensitive cells, they accumulate chemotherapeutics. Although our results neither directly prove nor disprove the hypothesis that P-glycoprotein is an ATP-driven drug efflux pump or "flippase," they demonstrate the existence of alternate pathways for MDR.
There are a number of potential therapeutic implications from this work. Iftumor cells are compromised in their ability to regulate pH, they may be more susceptible than healthy cells to pharmacological approaches that modify pH regulation. Thus, approaches that affect pH may potentiate the effects of the chemotherapeutic agents and, in this manner, reverse MDR.
Cell Biology. In the article "Intracellular pH and the control of multidrug resistance" by Sanford Simon, Deborshi Roy, and Melvin Schindler, which appeared in number 3, February 1, 1994, of Proc. Natl. Acad. Sci. USA (91, 1128-1132), one of the curves (for drug-sensitive cells in 5% C02) was omitted from Fig 
